Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Commercial Insight - Osteoporosis - Risk management and reformulation offer best defense against generic onslaught (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 27/06/2007
- Report Title: Commercial Insight - Osteoporosis - Risk management and reformulation offer best defense against generic onslaught
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 95
Introduction
The osteoporosis market is due a major upheaval when market leader Fosamax (alendronate) loses its US patent. The resultant heightened competition will force market players to implement radical lifecycle management strategies to safeguard their franchise revenue. New market entrants provide further complexity to the competitive landscape but will also drive market growth over the next ten years.
Scope
This report focuses on the leading therapies used in osteoporosis, with sales and volume country- and indication-specific forecasts to 2016
Assessment of current and future opportunities and threats in the osteoporosis market across the seven major pharmaceutical markets
Future market events that are expected to affect drug revenues are discussed and quantified for each of the seven major markets
Lifecycle management case studies show how previously successful strategies should be applied in today's market
Highlights
Reformulations of marketed products have helped rejuvenate the calcitonin and bisphosphonate markets amid genericization. Arguably the most exciting is the Roche's Boniva (ibandronate) reformulation which will generate substantial revenue as both an oral monthly and injectable quarterly product.
Following a number of recent reports that have concluded that vitamin D and calcium supplementation decreases the risk of cancer there is further support for the strategy to include a popular supplementary medication as either a combination pill or separately within the prescription brand packaging.
Eli Lilly has successfully launched two very different therapies to treat osteoporosis. Evista (raloxifene) and Forteo (teriparatide) The two products have been successful, being the third and fourth highest selling products on the osteoporosis market. In 2006, Evista generated sales of $739m and Forteo returned revenue of $574m.
Reasons to Purchase
Assess the impact of events such as patent expiries and new product launches on the osteoporosis sales of key marketed products
Quantify the future size of the osteoporosis market, in terms of volume and value, in each of the seven major markets
Identify key lifecycle management strategies that can ensure long term growth in the competitive osteoporosis market
The osteoporosis market is due a major upheaval when market leader Fosamax (alendronate) loses its US patent. The resultant heightened competition will force market players to implement radical lifecycle management strategies to safeguard their franchise revenue. New market entrants provide further complexity to the competitive landscape but will also drive market growth over the next ten years.
Scope
This report focuses on the leading therapies used in osteoporosis, with sales and volume country- and indication-specific forecasts to 2016
Assessment of current and future opportunities and threats in the osteoporosis market across the seven major pharmaceutical markets
Future market events that are expected to affect drug revenues are discussed and quantified for each of the seven major markets
Lifecycle management case studies show how previously successful strategies should be applied in today's market
Highlights
Reformulations of marketed products have helped rejuvenate the calcitonin and bisphosphonate markets amid genericization. Arguably the most exciting is the Roche's Boniva (ibandronate) reformulation which will generate substantial revenue as both an oral monthly and injectable quarterly product.
Following a number of recent reports that have concluded that vitamin D and calcium supplementation decreases the risk of cancer there is further support for the strategy to include a popular supplementary medication as either a combination pill or separately within the prescription brand packaging.
Eli Lilly has successfully launched two very different therapies to treat osteoporosis. Evista (raloxifene) and Forteo (teriparatide) The two products have been successful, being the third and fourth highest selling products on the osteoporosis market. In 2006, Evista generated sales of $739m and Forteo returned revenue of $574m.
Reasons to Purchase
Assess the impact of events such as patent expiries and new product launches on the osteoporosis sales of key marketed products
Quantify the future size of the osteoporosis market, in terms of volume and value, in each of the seven major markets
Identify key lifecycle management strategies that can ensure long term growth in the competitive osteoporosis market
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
